The cost-effectiveness of preexposure prophylaxis for HIV prevention in the united states in men who have sex with men

Annals of Internal Medicine

Volumn 156, Issue 8, 2012, Pages 541-550

  Juusola, Jessie L ^a   Brandeau, Margaret L ^a   Owens, Douglas K ^b   Bendavid, Eran ^b  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT; ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MONEY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED STATES;

EID: 84859771317     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-156-8-201204170-00001     Document Type: Article

References (91)

1. Centers for Disease Control and Prevention. Estimates of New HIV Infections in the United States; 2008. Atlanta, GA: Centers for Disease Control and Prevention; 2008. Accessed at www.cdc.gov/nchhstp/newsroom/docs/Fact-Sheet-on-HIV-Estimates.pdf on 1 March 2012.
2. Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F, et al; HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6:e17502. [PMID: 21826193]
3. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587-99. [PMID: 21091279]
4. Centers for Disease Control and Prevention (CDC). Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60:65-8. [PMID: 21270743]
5. Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48: 806-15. [PMID: 19193111]
6. Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22:1829-39. [PMID: 18753932]
7. Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS. 2011;25:1779-87. [PMID: 21716076]
8. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
9. Centers for Disease Control and Prevention. HIV and AIDS Among Gay and Bisexual Men. CDC Fact Sheet. Atlanta, GA: Centers for Disease Control and Prevention; 2010. Accessed at www.cdc.gov/nchhstp/newsroom/docs/FastFacts-MSM-FINAL508COMP.pdf on 21 February 2012.
10. U.S. Census Bureau, Population Division. National Population Projections, Released 2008 (Based on Census 2000). Washington, DC: U.S. Census Bureau; 2008. Accessed at www.census.gov/population/www/projections/downloadablefiles.html on 21 February 2012.
11. Centers for Disease Control and Prevention (CDC). HIV prevalence estimates-United States, 2006. MMWR Morb. Mortal Wkly Rep. 2008;57: 1073-6. [PMID: 18830210]
12. Xu F, Sternberg MR, Markowitz LE. Men who have sex with men in the United States: demographic and behavioral characteristics and prevalence of HIV and HSV-2 infection: results from National Health and Nutrition Examination Survey 2001-2006. Sex Transm Dis. 2010;37:399-405. [PMID: 20473245]
13. Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56:1-39. [PMID: 18274319]
14. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al; Quest Study. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189:1785-92. [PMID: 15122514]
15. Vergis EN, Mellors JW. Natural history of HIV-1 infection. Infect Dis Clin North Am. 2000;14:809-25, v-vi. [PMID: 11144640]
16. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198:687-93. [PMID: 18662132]
17. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS. 2007;21:1625-9. [PMID: 17630558]
18. Xiridou M, Geskus R, de Wit J, Coutinho R, Kretzschmar M. Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS. 2004;18:1311-20. [PMID: 15362664]
19. Long EF, Brandeau ML, Owens DK. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. Vaccine. 2009;27:5402-10. [PMID: 19591796]
20. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54. [PMID: 9182471]
21. Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, et al; HIV Paediatric Prognostic Markers Collaborative Study (HPPMCS). Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. J Infect Dis. 2008;197:398-404. [PMID: 18248303]
22. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153:778-89. [PMID: 21173412]
23. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, Thiebaut R, et al; Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007;21:1185-97. [PMID: 17502729]
24. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372:293-9. [PMID: 18657708]
25. Xiridou M, Geskus R, De Wit J, Coutinho R, Kretzschmar M. The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam. AIDS. 2003;17:1029-38. [PMID: 12700453]
26. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis. 2007;44:1115-22. [PMID: 17366461]
27. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-9. [PMID: 15809897]
28. Centers for Disease Control and Prevention. HIV Testing Survey, 2002. HIV/AIDS Surveillance Special Report-Number 5. Atlanta, GA: Centers for Disease Control and Prevention; 2006. Accessed at www.cdc.gov/hiv/surveillance/resources/reports/2004spec_no5/ on 21 February 2012.
29. Koblin BA, Chesney MA, Husnik MJ, Bozeman S, Celum CL, Buchbinder S, et al; EXPLORE Study Team. High-risk behaviors among men who have sex with men in 6 US cities: baseline data from the EXPLORE Study. Am J Public Health. 2003;93:926-32. [PMID: 12773357]
30. Colfax GN, Buchbinder SP, Cornelisse PG, Vittinghoff E, Mayer K, Ce-lum C. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS. 2002;16:1529-35. [PMID: 12131191]
31. Pathela P, Hajat A, Schillinger J, Blank S, Sell R, Mostashari F. Discordance between sexual behavior and self-reported sexual identity: a population-based survey of New York City men. Ann Intern Med. 2006;145:416-25. [PMID: 16983129]
32. Harawa NT, Greenland S, Bingham TA, Johnson DF, Cochran SD, Cunningham WE, et al. Associations of race/ethnicity with HIV prevalence and HIV-related behaviors among young men who have sex with men in 7 urban centers in the United States. J Acquir Immune Defic Syndr. 2004;35:526-36. [PMID: 15021318]
33. MacKellar DA, Valleroy LA, Behel S, Secura GM, Bingham T, Celentano DD, et al. Unintentional HIV exposures from young men who have sex with men who disclose being HIV-negative. AIDS. 2006;20:1637-44. [PMID: 16868445]
34. Rietmeijer CA, Wolitski RJ, Fishbein M, Corby NH, Cohn DL. Sex hustling, injection drug use, and non-gay identification by men who have sex with men. Associations with high-risk sexual behaviors and condom use. Sex Transm Dis. 1998;25:353-60. [PMID: 9713915]
35. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Ry-dzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352:570-85. [PMID: 15703422]
36. Teshale EH, Kamimoto L, Harris N, Li J, Wang H, McKenna MT. Estimated number of HIV-infected persons eligible for and receiving HIV antiretro-viral therapy, 2003 United States [Abstract]. Presented at 12th Conference on Retroviruses and Opportunistic Infections, Boston, 22-25 February 2005. Abstract 167.
37. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Ku-marasamy N, et al; HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505. [PMID: 21767103]
38. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. 2008; 372:314-20. [PMID: 18657710]
39. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342: 921-9. [PMID: 10738050]
40. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV transmission under highly active antiretroviral therapy [Letter]. Lancet. 2008;372:1806-7; author reply 1807. [PMID: 19027479]
41. The National Institute of Mental Health (NIMH) Multisite HIV Prevention Trial Group. The NIMH Multisite HIV Prevention Trial: reducing HIV sexual risk behavior. Science. 1998;280:1889-94. [PMID: 9632382]
42. Kamb ML, Fishbein M, Douglas JM Jr, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA. 1998;280:1161-7. [PMID: 9777816]
43. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr. 2006;41:632-41. [PMID: 16652038]
44. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591-601. [PMID: 17438318]
45. Sanchez T, Finlayson T, Drake A, Behel S, Cribbin M, Dinenno E, et al; Centers for Disease Control and Prevention (CDC). Human immunodeficiency virus (HIV) risk, prevention, and testing behaviors-United States, National HIV Behavioral Surveillance System: men who have sex with men, November 2003-April 2005. MMWR Surveill Summ. 2006;55(6):1-16. [PMID: 16826162]
46. Manning SE, Thorpe LE, Ramaswamy C, Hajat A, Marx MA, Karpati AM, et al. Estimation of HIV prevalence, risk factors, and testing frequency among sexually active men who have sex with men, aged 18-64 years-New York City, 2002. J Urban Health. 2007;84:212-25. [PMID: 17295058]
47. Rose CD, Courtenay-Quirk C, Knight K, Shade SB, Vittinghoff E, Gomez C, et al. HIV intervention for providers study: a randomized controlled trial of a clinician-delivered HIV risk-reduction intervention for HIV-positive people. J Acquir Immune Defic Syndr. 2010;55:572-81. [PMID: 20827218]
48. Steward WT, Remien RH, Higgins JA, Dubrow R, Pinkerton SD, Sik-kema KJ, et al. Behavior change following diagnosis with acute/early HIV infection-a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. AIDS Behav. 2009;13:1054-60. [PMID: 19504178]
49. Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39:446-53. [PMID: 16010168]
50. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemi-ologic features of primary HIV infection. Ann Intern Med. 1996;125:257-64. [PMID: 8678387]
51. Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al; Los Angeles County Primary HIV Infection Recruitment Network. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med. 2001;134:25-9. [PMID: 11187417]
52. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, et al; HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344:817-23. [PMID: 11248159]
53. Schackman BR, Gebo KA, Walensky RP, Losina E, Muccio T, Sax PE, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990-7. [PMID: 17063130]
54. Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Nosyk B, et al. Determinants of the cost of health services used by veterans with HIV. Med Care. 2011;49:848-56. [PMID: 21610542]
55. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 1999; 13:963-9. [PMID: 10371178]
56. Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43:451-7. [PMID: 16980906]
57. Meara E, White C, Cutler DM. Trends in medical spending by age, 1963-2000. Health Aff (Millwood). 2004;23:176-83. [PMID: 15318578]
58. Thomson PDR. Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Reuters; 2010.
59. Centers for Medicare & Medicaid Services. Medicare Information for Providers, Partners and Health Care Professionals. Baltimore: Centers for Medicare & Medicaid Services; 2010. Accessed at www.cms.gov/home/medicare.asp on 21 February 2012.
60. Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 2008;123 Suppl 3:51-62. [PMID: 19166089]
61. Paltiel AD, Walensky RP, Schackman BR, Seage GR 3rd, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145: 797-806. [PMID: 17146064]
62. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1-17. [PMID: 16988643]
63. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300:555-70. [PMID: 18677028]
64. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2011:1-167. Accessed at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf on 21 February 2011.
65. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25:63-71. [PMID: 21284497]
66. Golub SA, Operario D, Gorbach PM. Pre-exposure prophylaxis state of the science: empirical analogies for research and implementation. Curr HIV/AIDS Rep. 2010;7:201-9. [PMID: 20809218]
67. Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54:548-55. [PMID: 20512046]
68. Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24:689-91. [PMID: 20863247]
69. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77-83. [PMID: 19295337]
70. Liu AY, Kittredge PV, Vittinghoff E, Raymond HF, Ahrens K, Matheson T, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47:241-7. [PMID: 18340656]
71. Honiden S, Sundaram V, Nease RF, Holodniy M, Lazzeroni LC, Zolopa A, et al. The effect of diagnosis with HIV infection on health-related quality of Life. Qual Life Res. 2006;15:69-82. [PMID: 16411032]
72. CDC trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals [news release]. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Accessed at http://cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html on 24 February 2012.
73. Owens DK, Qaseem A, Chou R, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate the benefits, harms, and costs of medical interventions. Ann Intern Med. 2011;154:174-80. [PMID: 21282697]
74. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8:e1000423. [PMID: 21390264]
75. Kaplan EH. Economic analysis of needle exchange [Editorial]. AIDS. 1995; 9:1113-9. [PMID: 8519446]
76. CensusScope. United States Age Distribution; 2000. Ann Arbor, MI: Social Science Data Analysis Network; 2000. Accessed at www.censusscope.org/us/chart_age.html on 24 February 2012.
77. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102. [PMID: 8483408]
78. Bollinger RC, Brookmeyer RS, Mehendale SM, Paranjape RS, Shepherd ME, Gadkari DA, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA. 1997;278:2085-9. [PMID: 9403423]
79. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009. Ann Intern Med. 2009;151:829-39. [PMID: 20008759]
80. Turner DA, Wailoo AJ, Cooper NJ, Sutton AJ, Abrams KR, Nicholson KG. The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age. Vaccine. 2006;24:1035-43. [PMID: 16183177]
81. O'Brien BJ, Goeree R, Blackhouse G, Smieja M, Loeb M. Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and costeffectiveness model for Canada. Value Health. 2003;6:116-25. [PMID: 12641862]
82. Neuner JM, Hamel MB, Phillips RS, Bona K, Aronson MD. Diagnosis and management of adults with pharyngitis. A cost-effectiveness analysis. Ann Intern Med. 2003;139:113-22. [PMID: 12859161]
83. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:54-62. [PMID: 9377126]
84. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475-81. [PMID: 12458977]
85. Nyman JA, Barleen NA, Dowd BE, Russell DW, Coons SJ, Sullivan PW. Quality-of-life weights for the US population: self-reported health status and priority health conditions, by demographic characteristics. Med Care. 2007;45: 618-28. [PMID: 17571010]
86. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006;26:410-20. [PMID: 16855129]
87. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS. 2006;20:2207-15. [PMID: 17086061]
88. Owens DK, Nease RF Jr, Harris RA. Cost-effectiveness of HIV screening in acute care settings. Arch Intern Med. 1996;156:394-404. [PMID: 8607724]
89. Mylonakis E, Paliou M, Lally M, Flanigan TP, Rich JD. Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. Am J Med. 2000;109:568-76. [PMID: 11063959]
90. Greenwald JL, Burstein GR, Pincus J, Branson B. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006;8:125-31. [PMID: 16524549]
91. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, Zhang H, et al. Expanded screening for HIV in the United States-an analysis of cost-effectiveness. N Engl J Med. 2005;352:586-95. [PMID: 15703423]